Attached files

file filename
EX-23.1 - EX-23.1 - MELINTA THERAPEUTICS, INC. /NEW/cemp-ex231_9.htm
EX-32.1 - EX-32.1 - MELINTA THERAPEUTICS, INC. /NEW/cemp-ex321_10.htm
EX-31.1 - EX-31.1 - MELINTA THERAPEUTICS, INC. /NEW/cemp-ex311_11.htm
EX-10.35 - EX-10.35 - MELINTA THERAPEUTICS, INC. /NEW/cemp-ex1035_842.htm
10-K - 10-K - MELINTA THERAPEUTICS, INC. /NEW/cemp-10k_20151231.htm
EX-31.2 - EX-31.2 - MELINTA THERAPEUTICS, INC. /NEW/cemp-ex312_7.htm
EX-10.34 - EX-10.34 - MELINTA THERAPEUTICS, INC. /NEW/cemp-ex1034_961.htm

 

Exhibit 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report on Form 10-K of Cempra, Inc. (the “Company”) for the fiscal year ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark W. Hahn, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 25, 2016

 

/s/ Mark W. Hahn

 

Mark W. Hahn

 

Chief Financial Officer (Principal Financial Officer)